Off-the-shelf compositions for target genes
We developed advanced gene editing compositions for multiple genes to treat different diseases using our novel proprietary OMNI nucleases. These gene editing compositions were validated using several systems from computational through human cell-line to target cells validations. Each solution was adjusted to the specific editing requirements of the diseases including allele specific knockout (KO), the use of non-NGG nucleases and the use of a variety of nucleases with different sizes to fit different delivery modalities. These compositions are available for out-licensing and can be adjusted to fit your needs.
Custom nucleases
We use our in-house AI-based computational engineering platform to predict optimal nuclease variants based on the customer’s requirements. These predicted variants are then tested in our high- throughput screening systems to validate their improved efficacy. We offer the optimal variants to our collaborators and licensees via out-licensing agreements. All our validated nucleases are highly active and highly specific.Consulting services
EmendoBio is an expert in gene editing with vast experience in the discovery of novel nucleases, engineering them, and development of CRISPR based gene editing compositions. We offer our partners consulting services in several areas including gene editing strategy design, gRNA selection, off-target experiments and analysis, and more.
Partners
EmendoBio’s OMNI platform has expanded the CRISPR nuclease toolbox and currently provides a great variety of CRISPR gene editing based solutions. We believe in the power of partnerships to drive innovation and create a lasting sustainable value and believe that our OMNI platform can contribute greatly to the development of novel CRISPR based therapies. We offer our OMNI nucleases for out licensing and welcome strategic collaborations to integrate OMNI nucleases in the development of novel therapies.
Our Collaborators and Licensees
Contact Our Business Development Team
Please email us at bd@emendobio.com and we shall get back to you shortly.